A total of 285 (11.8%) clients were on TB treatment at baseline, this proportion ranged from 25.7% among those with CD4 counts ≤200 cells/μL down to 5.2% among those with counts >500 cells/μL. The gene discussed is CD4; the disease is tuberculosis.